-
Digital technology + pharmaceutical equipment, or open up a broader market space
Time of Update: 2021-11-14
The industry pointed out that digital technology + pharmaceutical equipment will help companies open up a broader market space .
As more and more pharmaceutical machinery companies gradually transform and upgrade from traditional single equipment suppliers to system integrators and solution providers, they will bring more benefits to customers and create greater value .
-
Corning Jerry appoints Han Jing as chief commercial officer
Time of Update: 2021-11-14
Han Jing has extensive commercialization experience in multinational and local pharmaceutical companies, and has led the team to successfully promote outstanding innovative drugs to The market benefits the majority of patients .
-
The first domestic product! Connoa's MASP-2 monoclonal antibody was approved for clinical use
Time of Update: 2021-11-14
CM338 is the first domestic innovative monoclonal antibody drug targeting MASP-2 and the second clinically approved MASP-2 inhibitor in the world .
-
Chinese pharmaceutical companies continue to make efforts in the field of anti-epileptic drugs
Time of Update: 2021-11-14
As recently, CSPC's anti-epileptic drug Enrivi (lacosamide tablets) was launched nationwide .
. In addition, in June, the State Food and Drug Administration issued a new drug approval document, and Renfu Pharmaceutical's carbamazepine tablets had been evaluated for consistency .
-
A number of blockbuster new drugs have been approved for clinical use, and the R&D capabilities of local pharmaceutical companies have greatly improved
Time of Update: 2021-11-14
As of October 29, 2021, data from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration show that a total of 5670 clinical trial applications have passed "implicit permission .
According to data, in 2020, the Center for Drug Evaluation has approved 1,435 IND (New Drug Clinical Trial) applications, an increase of 54.
-
Announcement of the State Drug Administration on 18 batches of drugs that do not meet the requirements (No. 59 of 2021)
Time of Update: 2021-11-14
After inspection by Hubei Provincial Institute of Drug Supervision and Inspection, a batch of Atractylodes japonicus (fried atractylodes with bran) produced by Anhui Wukeng Chinese Medicine Decoction Pieces Co.
-
Notice on the public solicitation of opinions on two standards including "Principles for Printing of Drug Traceability Codes (Draft for Solicitation of Comments)"
Time of Update: 2021-11-14
Please fill in the standard feedback form for soliciting opinions (see Annex 3), and feedback to the Information Center of the State Food and Drug Administration in the form of e-mail before July 20, 2021 .
-
WOO SWEE LIAN, Chairman of Wise Medicine, resigns and by-elections Fan Shixin as non-independent director
Time of Update: 2021-11-14
On November 2, Ruizhi Medicine issued an announcement stating that the company’s board of directors had recently received a written resignation report from the company’s chairman, Mr.
-
Yangtze River Class 1 new drug for insomnia enters Phase 3 clinical trial
Time of Update: 2021-11-14
The trial data showed that YZJ-1139 can improve sleep by inhibiting orexin receptors.
This is the first orexin receptor antagonist that has completed Phase 2 clinical trials in China .
-
FDA approves multiple investigational new drug applications
Time of Update: 2021-11-14
” Theseus intends to initiate a phase I/II dose escalation and expansion clinical trial, which will include For patients with advanced GIST who have previously received treatment, the study is expected to start at the end of the fourth quarter of 2021 or the first quarter of 2022 .
-
Industry: In the fourth quarter, the performance of the pharmaceutical high-prosperity sector is expected to grow rapidly
Time of Update: 2021-11-14
Looking forward to the fourth quarter, the industry believes that the performance of the pharmaceutical high-prosperity sector is expected to grow rapidly, including CXO, medical devices, vaccines, medical services and APIs .
-
Approval of Sintilimab's new indication application for frustrated potential is still optimistic
Time of Update: 2021-11-14
However, due to unpredictable circumstances, Sintilimab received a drug notification for the first time in China, and the listing application for a single-drug second-line treatment of squamous non-small cell lung cancer was not approved .
-
The three major problems in the industry with the general price rise of Chinese herbal medicines are coming!
Time of Update: 2021-11-14
So, in the use of terminal demand is not prosperous, but the source of the production end is a growing boom in planting, and the supply of goods will continue to emerge in the future, and the market prices of many Chinese medicinal materials will always be as they are now.
-
Yantai: This is how the blueprint of the biomedical industry will be described!
Time of Update: 2021-11-14
In accordance with the layout principle of “coordinated linkage, intensive clustering, and characteristic development”, Yantai City will build a “1+3+X” biomedical industry spatial layout, namely, to create a life science innovation leading core area in the east, a high-end medical equipment cluster development area in the west, and a central area.
-
Pharmaceutical companies showed strong willingness to invest in R&D, allowing R&D to be in the “C” position
Time of Update: 2021-11-14
Data shows that in the first three quarters of this year, some listed pharmaceutical companies invested more than 100 million yuan in research and development, and their share of revenue continued to increase .
In recent years, China's pharmaceutical companies have continuously increased their R&D investment.
-
Qian Wei, Chief Commercial Officer of Junshi Biotechnology, resigns
Time of Update: 2021-11-14
On November 3, Junshi Biotech formally announced to its employees that the chief commercial officer Qian Wei has recently resigned to the company due to personal development reasons.
-
Investment Collection: Core financial indicators reveal the development of online and offline retail pharmacies
Time of Update: 2021-11-14
Figure 1: Comparison of core data in the three quarterly reports of offline drugstoresData source: iFinD, Zhongkang Industrial Capital Research CenterOnline Internet pharmacies are represented by Alibaba Health, JD Health, Ping An Good Doctor, and Yiyao.
-
The competitive landscape of the innovative drug industry is facing reconstruction, and FIC drugs are more favored by capital
Time of Update: 2021-11-14
Also in September, Yinming Bio, which is committed to the research and development of first-in-class drugs with global competitiveness, announced the completion of nearly US$50 million in A+ round of financing .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Carbimazole Tablets (No. 80 of 2021)
Time of Update: 2021-11-14
5. The provincial drug supervision and administration department shall supervise and urge the drug marketing license holders of the above-mentioned drugs in the administrative area to do the corresponding manual revision and label and manual replacement work as required, and strictly investigate and deal with violations of laws and regulations in accordance with the law .
-
Traditional Chinese medicine is ushering in a broad space for development, and the status of decocting machine is becoming more and more prominent
Time of Update: 2021-11-14
Therefore, in terms of automation and information technology improvement of the decocting machine, the industry still needs to make continuous efforts to better contribute to the sustainable development of traditional Chinese medicine .